Short-Term Continuous Subcutaneous Insulin Infusion Combined with Insulin Sensitizers Rosiglitazone, Metformin, or Antioxidant α-Lipoic Acid in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Схожие документы

• Attitudes Toward Diabetes Affect Maintenance of Drug-Free Remission in Patients With Newly Diagnosed Type 2 Diabetes After Short-Term Continuous Subcutaneous Insulin Infusion Treatment
  по: Chen, Ailing, et al.
  Опубликовано: (2012)
• Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study
  по: Ke, Weijian, et al.
  Опубликовано: (2016)
• Increased 1,5-Anhydroglucitol Predicts Glycemic Remission in Patients with Newly Diagnosed Type 2 Diabetes Treated with Short-Term Intensive Insulin Therapy
  по: Liu, Liehua, et al.
  Опубликовано: (2012)
• Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes
  по: Li, Feng-fei, et al.
  Опубликовано: (2018)
• Construction and Implications of Nomogram for Predicting Sustained Glycemic Remission After Short‐Term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes
  по: Lijuan Xu, et al.
  Опубликовано: (2025-08-01)